Three Decades of Enamel Matrix Derivative: From Dental Innovation to Extra-Oral Applications.

Introduction: Enamel matrix derivative (EMD; Emdogain) has been deployed for three decades as a biologically active material in periodontal regeneration. Widely adopted in periodontology, its indications are expanding into endodontics, ridge preservation, implantology, dermatology and oncology-related indication. Contemporary applications encompass vital pulp therapy, alveolar ridge preservation (ARP), peri-implantitis adjunctive therapy and soft-tissue wound healing. Materials and Methods: This narrative review synthesises English-language literature (1996-2025) retrieved from PubMed, Scopus and Cochrane Oral Health. The scope prioritised clinical outcomes in endodontic and periodontal contexts-recession coverage, intrabony and furcation defects, osteogenesis, peri-implantitis management and wound healing. Included were clinical trials (preferentially randomised controlled trials [RCTs]) with ≥6 months follow-up; selective animal studies were incorporated to clarify tissue-level and histologic mechanisms, particularly for endodontic applications. Results: Accumulated evidence indicates EMD augments the probability of complete root coverage (RC) and increases keratinised tissue (KT) width in mucogingival procedures. EMD, alone or adjunctive to bone grafts or membranes, improves clinical parameters in intrabony and certain furcation defects and demonstrates osteopromotive effects in preclinical and clinical models. Adjunctive use in peri-implantitis and implant-site regeneration shows promising amelioration of inflammatory and bone-regenerative endpoints. Conversely, EMD has limited efficacy for preservation of alveolar ridge dimensions post-extraction. In vital pulp therapy, EMD supports tertiary dentinogenesis and dentine-bridge formation. Mechanistically, EMD enhances cell migration, proliferation, extracellular matrix (ECM) deposition and angiogenesis. Preliminary data indicate potential utility in non-healing cutaneous ulcers, though evidence remains sparse. Conclusion: EMD is a validated adjunct in periodontal regeneration-particularly recession coverage and the management of intrabony defects-with encouraging osteogenic and reparative properties that extend to endodontic and wound-healing indications. Future investigations should standardise dosing/regimens, explore controlled-release and combination modalities and evaluate long-term clinical effectiveness and cost-benefit metrics.